His primary scientific interests are in Melanoma, Cancer research, Pathology, Immunology and Metastasis. His research integrates issues of Cell growth, Tumor microenvironment, T cell, Cytotoxic T cell and MAPK/ERK pathway in his study of Melanoma. His Cancer research study combines topics from a wide range of disciplines, such as Cell culture, Gene knockdown, Tumor progression, Regulation of gene expression and Drug resistance.
His work deals with themes such as Neurosphere and Adult stem cell, which intersect with Pathology. Xiaowei Xu combines subjects such as Embryonic stem cell, Targeted therapy, Stem cell, Melanocyte and Unfolded protein response with his study of Immunology. The study incorporates disciplines such as Surgery, Retrospective cohort study, Anatomical pathology and Perineural invasion in addition to Metastasis.
Xiaowei Xu spends much of his time researching Melanoma, Cancer research, Pathology, Internal medicine and Cancer. Xiaowei Xu has researched Melanoma in several fields, including Sentinel lymph node, Immune system, Immunology, Biopsy and Metastasis. His Cancer research research includes elements of Tumor progression, Cell, PI3K/AKT/mTOR pathway and Downregulation and upregulation.
His studies in Pathology integrate themes in fields like Lymphovascular invasion and Nevus. His biological study deals with issues like Endocrinology, which deal with fields such as Signal transduction. His Cancer study combines topics in areas such as Erythropoietin receptor, Erythropoietin and Combination therapy.
Xiaowei Xu mostly deals with Melanoma, Cancer research, Internal medicine, Immune system and Cancer. His Melanoma research incorporates elements of Tumor microenvironment, Biopsy, Pathology, Metastasis and Immunotherapy. Xiaowei Xu has included themes like Autophagy, Cell, Cancer cell, Neuroblastoma RAS viral oncogene homolog and Antibody in his Cancer research study.
The various areas that Xiaowei Xu examines in his Internal medicine study include Gastroenterology and Oncology. His Immune system research is multidisciplinary, incorporating elements of Cytotoxic T cell and Monoclonal antibody. As part of his studies on Cancer, Xiaowei Xu frequently links adjacent subjects like Drug resistance.
His scientific interests lie mostly in Cancer research, Melanoma, Tumor microenvironment, Immune system and Cell growth. The concepts of his Cancer research study are interwoven with issues in Autophagy, Apoptosis, Agonist, Downregulation and upregulation and Targeted therapy. His study in Melanoma is interdisciplinary in nature, drawing from both Neoadjuvant therapy, Internal medicine, Oncology and Monoclonal.
His studies deal with areas such as Wnt signaling pathway, Phenotype, Blockade, Adjuvant and Metastasis as well as Tumor microenvironment. His Cell growth research includes themes of Immune checkpoint, Cancer, Cancer cell, PD-L1 and Immunotherapy. His research in Cancer intersects with topics in Cell culture and Signal transduction.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor;Andrew J. Rech;Amit Maity;Ramesh Rengan;Ramesh Rengan.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma
Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang.
A tumorigenic subpopulation with stem cell properties in melanomas.
Dong Fang;Thiennga K. Nguyen;Kim Leishear;Rena Finko.
Cancer Research (2005)
Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
Gang Chen;Alexander C. Huang;Wei Zhang;Wei Zhang;Gao Zhang.
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva;Adina Vultur;John T. Lee;Rajasekharan Somasundaram.
Cancer Cell (2010)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang;Michael A. Postow;Michael A. Postow;Robert J. Orlowski;Rosemarie Mick.
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo;Lu Si;Yan Kong;Keith T. Flaherty.
Journal of Clinical Oncology (2011)
TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion
Omar Khan;Josephine R. Giles;Sierra McDonald;Sasikanth Manne.
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients
Thomas Condamine;George A. Dominguez;Je-In Youn;Andrew V. Kossenkov.
Science immunology (2016)
Isolation of a Novel Population of Multipotent Adult Stem Cells from Human Hair Follicles
Hong Yu;Dong Fang;Suresh M. Kumar;Ling Li.
American Journal of Pathology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: